Payment overview · 2025
General Payments
$267.53
10 reported records · 8 companies
Healthcare provider profile · identity verified
Pratheep Arora, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · COLORADO SPRINGS, CO · NPI 1467475616
Verified facts
What the public records show
CMS Open Payments records show Pratheep Arora, M.D. received $267.53 in general payments during 2025 across 10 reported records.
Amgen Inc. accounted for 26.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $71.46 | 26.7% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $57.32 | 21.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.64 | 11.1% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.24 | 9.4% | 1 | 2025 |
| Ossur Americas, Inc. | Unresolved — no canonical attribution shown | $24.20 | 9.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$22.39 | 8.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.76 | 7.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.52 | 6.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $267.53 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $71.46 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $57.32 | 1 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $29.64 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $25.24 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $18.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 698 | 212 |
| Amlodipine Besylate | Amlodipine Besylate | 449 | 148 |
| Lisinopril | Lisinopril | 428 | 144 |
| Metoprolol Succinate | Metoprolol Succinate | 377 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 322 | 85 |
| Omeprazole | Omeprazole | 260 | 74 |
| Losartan Potassium | Losartan Potassium | 237 | 81 |
| Furosemide | Furosemide | 220 | 76 |
| Metformin Hcl | Metformin Hcl | 210 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 200 | 65 |
| Potassium Chloride | Potassium Chloride | 187 | 76 |
| Gabapentin | Gabapentin | 186 | 68 |
| Trazodone Hcl | Trazodone Hcl | 181 | 49 |
| Jardiance | Empagliflozin | 169 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 47 |
| Simvastatin | Simvastatin | 134 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 127 | 44 |
| Allopurinol | Allopurinol | 125 | 34 |
| Carvedilol | Carvedilol | 122 | 40 |
| Alendronate Sodium | Alendronate Sodium | 111 | 30 |
| Trulicity | Dulaglutide | 107 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 100 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 27 |
| Meloxicam | Meloxicam | 98 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 26 |
| Prednisone | Prednisone | 80 | 48 |
| Eliquis | Apixaban | 78 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 27 |
| Ozempic | Semaglutide | 71 | 18 |
| Ezetimibe | Ezetimibe | 66 | 20 |
| Famotidine | Famotidine | 66 | 19 |
| Glimepiride | Glimepiride | 65 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 18 |
| Bumetanide | Bumetanide | 59 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 25 |
| Fenofibrate | Fenofibrate Nanocrystallized | 58 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 56 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 11 |
| Finasteride | Finasteride | 54 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 18 |
| Chlorthalidone | Chlorthalidone | 51 | 24 |
| Prosol | Parenteral Amino Acid 20% No.1 | 51 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 50 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 26 |
| Montelukast Sodium | Montelukast Sodium | 49 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 39 |
| Atenolol | Atenolol | 43 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 22 |
| Sertraline Hcl | Sertraline Hcl | 43 | 16 |
| Buspirone Hcl | Buspirone Hcl | 42 | 12 |
| Lactulose | Lactulose | 40 | 16 |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Celecoxib | Celecoxib | 38 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 11 |
| Invokana | Canagliflozin | 37 | suppressed |
| Linzess | Linaclotide | 37 | 14 |
| Clonidine | Clonidine | 36 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 11 |
| Mometasone Furoate | Mometasone Furoate | 33 | 19 |
| Pregabalin | Pregabalin | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 16 |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | 14 |
| Telmisartan | Telmisartan | 32 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 27 |
| Ibuprofen | Ibuprofen | 30 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 30 | 11 |
| Azithromycin | Azithromycin | 29 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Calcitriol | Calcitriol | 28 | 12 |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Metolazone | Metolazone | 26 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | 12 |
| Topiramate | Topiramate | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 19 |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Calcium Acetate | Calcium Acetate | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Klor-Con | Potassium Chloride | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $267.53 · 10 records | Amgen Inc. | INSPIRE, JYNARQUE, KRYSTEXXA, MINIMED 780G, PURIFIED CORTROPHIN GEL, VYNDAQEL, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error